SCHEMBL1435656

SCHEMBL1435656

Nc1ccc(NC(=O)c2ccc(CN(C=O)OCc3cccnc3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.50
EPAS1 Q99814 2/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 1/20 0.46
HDAC1 Q13547 5/20 0.45
HDAC3 O15379 1/20 0.45
KDM1A O60341 1/20 0.45
F3 P13726 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
NCOR2 Q9Y618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1435353 0.90 TRPV1 (0.44) HIF1AEPAS1CYP3A4HDAC1HDAC3
SCHEMBL302457 0.85 HDAC1 (0.63) CYP3A4HDAC1HDAC3KDM1AF3
Bromide SCHEMBL2409900 0.85 HDAC1 (0.62) CYP3A4HDAC1HDAC3KDM1AF3
Hydrochloric Acid SCHEMBL2407989 0.85 HDAC1 (0.62) CYP3A4HDAC1HDAC3KDM1AF3
SCHEMBL3559032 0.82 HDAC1 (0.62) MEN1KMT2ACYP3A4HDAC1HDAC3
SCHEMBL2413630 0.82 HDAC1 (0.66) CYP3A4HDAC1HDAC3KDM1AF3
SCHEMBL2416256 0.82 HDAC1 (0.66) CYP3A4HDAC1HDAC3KDM1AF3
SCHEMBL2414034 0.81 HDAC1 (0.51) CYP3A4HDAC1HDAC3KDM1AF3
SCHEMBL2410013 0.80 HDAC1 (0.67) CYP3A4HDAC1HDAC3KDM1AF3
SCHEMBL2413954 0.79 HDAC1 (0.53) KMT2AHDAC1HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437346-B9 Benzamide derivatives useful as cell differentiation inducers Bayer Pharma AG (DE) 2011-09-28 EP disclosed
US-8026239-B2 Cell differentiation inducer BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-09-27 US disclosed
EP-1437346-B1 Benzamide derivatives useful as cell differentiation inducers BAYER SCHERING PHARMA AG (DE) 2011-03-30 EP disclosed
US-20100256201-A1 CELL DIFFERENTIATION INDUCER BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-07 US disclosed
US-7687525-B2 Cell differentiation inducer BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-03-30 US disclosed
US-20080188489-A1 Cell differentiation inducer SCHERING AKTIENGESELLSCHAFT (DE) 2008-08-07 US disclosed
US-7317028-B2 Cell differentiation inducer SCHERING AKTIENGESELLSCHAFT (DE) 2008-01-08 US disclosed
US-RE39754-E1 Benzamide derivatives and pharmaceutical compositions containing same SCHERING AG (DE) 2007-07-31 US disclosed
US-6794392-B1 Cell differentiation inducer SCHERING AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20040147569-A1 Antitumor agents; autoimmune disease; skin disorders; anticancer agents SCHERING AKTIENGESELLSCHAFT 2004-07-29 US disclosed
EP-1437346-A1 Benzamide derivatives useful as cell differentiation inducers Schering AG (DE) 2004-07-14 EP disclosed
US-6174905-B1 AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA MITSUI CHEMICALS, INC. (JP) 2001-01-16 US disclosed
EP-0847992-A1 Benzamide derivatives, useful as cell differentiation inducers Mitsui Chemicals, Inc. (JP) 1998-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188489-A1 Cell differentiation inducer MCL1, MYADM, MYD88 HIF1A 899/4885EPAS1 888/4885MEN1 1515/4885
US-20040147569-A1 Antitumor agents; autoimmune disease; skin disorders; anticancer agents MCL1, MYADM, PDCD1 HIF1A 497/4885EPAS1 1107/4885MEN1 376/4885
US-20100256201-A1 CELL DIFFERENTIATION INDUCER MCL1, MYADM, MYD88 HIF1A 961/4885EPAS1 917/4885MEN1 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.